Joint Publication with Kite Pharma and NCI in Blood Journal: Preinfusion Polyfunctional Anti-CD19 Chimeric Antigen Receptor T Cells Associate with Clinical Outcomes in NHL

Research recently published in the journal Blood — conducted in a collaborative effort with Kite Pharma, a Gilead company — demonstrates a significant association between the functionality of an anti-CD19 CAR-T cell product before treatment, as defined by IsoPlexis’ Polyfunctional Strength Index (PSI), and the objective response in patients with non-Hodgkin lymphoma (NHL). “The results highlight the potential to predict whether cancer patients will respond to CAR-T cell therapy before treatment, as well as to improve both pre-infusion product potency testing and guide cell product optimization.

Share This Article
Be in the Know.
Subscribe to the IsoPlexis Blog
Join 10,000+ top scientists and receive industry pioneers' backed data straight to your inbox.
Your data is in safe hands! We'll never share or sell your data to any third parties, and you may unsubscribe at any time.